Brief: Vaccitech Doses First Patients In HBV003, A Phase 2B Clinical Trial Of VTP-300 Immunotherapeutic Candidate For Chronic HBV Patients
31/10/2022 12:12
Oct 31 (Reuters) - Vaccitech PLC VACC.O :
* VACCITECH DOSES FIRST PATIENTS IN HBV003, A PHASE 2B
CLINICAL
TRIAL OF VTP-300 IMMUNOTHERAPEUTIC CANDIDATE FOR CHRONIC HBV
PATIENTS
Source text for Eikon: ID:nGNX9V928h
Further company coverage: VACC.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing